An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
The Rogers Foundation announces a second landmark gift, building on its $130 million gift in 2014, to sustain the Ted Rogers Centre for Heart Research in perpetuity and bring the promise of precision cardiac health to patients across Canada and globally. In 2014, the...
Ted Rogers Chair in Heart Function Outcomes Dr. Douglas Lee leads new Heart-Brain Connection $3 million IMPACT Award project
Four unique educational events in October and December
Almost 20 years ago, a hallway conversation kickstarted Dr. Mansoor Husain’s journey in helping create and test a new diabetes drug that reduces the risk of heart disease.
In 2019, the Ted Rogers Centre for Heart Research executive director published the findings of a landmark trial proving the drug’s safety and reduction in cardiovascular-related mortality, bringing a new therapy into the fold for patients with diabetes – who are two to four times more likely to die from cardiovascular problems than those without it.
In this podcast, produced by University Health Network, explore the fascinating intersection of type 2 diabetes and heart failure, and the recent journey to discover that treatments for the former can be effective for the latter.
